Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Cardiometabolic Risk

CoverageCardiometabolic Risk

Should aspirin be used for primary cardiovascular prevention?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: postmenopausal women

Bottom line

Current guidelines generally discourage routine aspirin for primary prevention in low-to-moderate-risk adults because bleeding harm offsets modest benefit. Select high-risk individuals may still be considered with shared decision-making.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Net benefit in borderline-risk adults depends on bleeding risk and evolving guideline thresholds.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Should I take aspirin for heart attack prevention?▼

Current guidelines do not recommend routine low-dose aspirin for primary cardiovascular prevention in most adults due to bleeding risk offsetting cardiovascular benefit, particularly in older adults.

Aspirin primary prevention USPSTF▼

The USPSTF 2022 guidance recommends initiating low-dose aspirin for primary prevention only in adults aged 40–59 at ≥10% 10-year CVD risk, after individual benefit-harm discussion. It recommends against starting in adults ≥60.

Can aspirin cause stomach bleeding?▼

Yes — aspirin increases gastrointestinal bleeding risk even at low doses. This risk rises with age and outweighs cardiovascular benefit in most primary prevention settings, which is why guidelines shifted against routine use.

Aspirin for stroke prevention▼

Aspirin for primary stroke prevention is not supported in most adults due to bleeding risk. It remains indicated for secondary prevention after ischemic stroke or TIA.

Aspirin prevention guidelines▼

Current guidelines generally discourage routine aspirin for primary prevention in low-to-moderate-risk adults because bleeding harm offsets modest benefit. Select high-risk individuals may still be considered with shared decision-making.

Low-dose aspirin healthy adults▼

Current guidelines generally discourage routine aspirin for primary prevention in low-to-moderate-risk adults because bleeding harm offsets modest benefit. Select high-risk individuals may still be considered with shared decision-making.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 13 relevant studies.

Overall finding

6 studies address ldl-c, with weighted findings showing harm. 4 studies address major adverse cardiovascular events, with weighted findings showing harm. 3 studies address mortality, with weighted findings showing mixed findings. 1 study addresses venous thromboembolism, with weighted findings showing unclear findings. 3 randomized or systematic-review reports and 1 observational study address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Harm signal

LDL-C

moderate · 6 studies

6 studies address ldl-c, with weighted findings showing harm. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 30415628PMID 31447131PMID 22607822PMID 18997196PMID 34773460PMID 38700053
Harm signal

Major adverse cardiovascular events

high · 4 studies

4 studies address major adverse cardiovascular events, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 30146931PMID 30158069PMID 30415628PMID 18997196
Mixed

Mortality

moderate · 3 studies

3 studies address mortality, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 30158069PMID 30415628PMID 22607822
Unclear

Venous thromboembolism

moderate · 1 study

1 study addresses venous thromboembolism, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37326322
Unclear

HbA1c / glycemic control

moderate · 1 study

1 study addresses hba1c / glycemic control, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 10100178
Unclear

Weight / body composition

moderate · 1 study

1 study addresses weight / body composition, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 10100178

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 60; RR 0; hazard ratio 1.06. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Findings are mixed after weighting by design, quality, and directness.

Supports main conclusion: 6 · Neutral / mixed: 7 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain.
  • In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascul…
  • The use of aspirin in the primary prevention of cardiovascular events remains controversial.
  • Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosa…

Risks & harms

4 studies report safety-relevant findings. Design mix: Randomized controlled trial. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

The evidence set is heterogeneous. The most recurrent population is postmenopausal women, but several distinct groups were studied.

What remains uncertain

  • Net benefit in borderline-risk adults depends on bleeding risk and evolving guideline thresholds.
  • Net benefit in borderline-risk adults depends on bleeding risk and evolving guideline thresholds.

Clinical takeaway

Avoid routine aspirin for primary prevention in low-to-moderate-risk adults given bleeding risk. Reserve shared decision-making for selected higher-risk individuals where net benefit may still favor use.

Harm signal

LDL-C?

Harm

moderate[30415628 · 31447131 · 22607822 · 18997196 · 34773460 · 38700053]

Harm signal

Major adverse cardiovascular events?

Harm

high[30146931 · 30158069 · 30415628 · 18997196]

Mixed

Mortality?

Mixed findings

moderate[30158069 · 30415628 · 22607822]

Unclear

Venous thromboembolism?

Unclear findings

moderate[37326322]

Unclear

HbA1c / glycemic control?

Unclear findings

moderate[10100178]

Unclear

Weight / body composition?

Unclear findings

moderate[10100178]

Unclear

Apolipoprotein B?

Unclear findings

limited[34773460 · 38700053]

3 randomized or systematic-review reports and 1 observational study address treatment. Weighted treatment findings show unclear findings.

3 RCT / systematic review · 1 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

13 analyzed studies

Strongest evidence

The New England journal of medicine2018

Landmark studyPMID 30146931

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard.

RCT
Evidence
Relevance

Supporting literature

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Cardiometabolic Risk.

Is ApoB more useful than LDL-C for cardiovascular risk prediction?

Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.

14 linked studies

Should adults take statins for primary cardiovascular prevention?

Meta-analyses of primary prevention trials show reduced major adverse cardiovascular events with statins in appropriately selected moderate-to-high-risk adults. Shared decision-making should weigh absolute risk reduction against side effects and patient preference.

12 linked studies

Does elevated lipoprotein(a) independently increase cardiovascular risk?

Mendelian randomization and epidemiologic data support Lp(a) as a causal cardiovascular risk factor. Specific Lp(a)-lowering therapies are emerging but routine treatment beyond standard risk factor control awaits outcome trial confirmation.

11 linked studies

Does hormone therapy improve metabolic syndrome markers?

Menopausal hormone therapy may favorably affect some metabolic markers in selected women but is not a primary treatment for metabolic syndrome. Lifestyle and cardiometabolic risk management remain foundational.

14 linked studies

Go deeper on Cardiometabolic Risk

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Cardiometabolic RiskView pricing